Core Viewpoint - Novocure has received FDA approval for Optune Pax® to treat adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, marking a significant advancement in cancer treatment options [1] Group 1: FDA Approval - The FDA approved Optune Pax® for use in adult patients with locally advanced pancreatic cancer [1] - This approval is based on the results from the Phase 3 PANOVA-3 trial [1] Group 2: Clinical Trial Results - The PANOVA-3 trial demonstrated a statistically significant improvement in overall survival for patients treated with Optune Pax® [1] - Importantly, the treatment did not add to the systemic side effects typically associated with existing therapies [1]